Lynne Ward Sells 5,000 Shares of Merit Medical Systems (NASDAQ:MMSI) Stock

Merit Medical Systems, Inc. (NASDAQ:MMSI) Director Lynne Ward sold 5,000 shares of Merit Medical Systems stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $62.61, for a total value of $313,050.00. Following the transaction, the director owned 7,809 shares of the company’s stock, valued at $488,921.49. The trade was a 39.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Merit Medical Systems Stock Performance

Merit Medical Systems stock traded down $0.13 during midday trading on Monday, reaching $61.15. 226,354 shares of the company’s stock were exchanged, compared to its average volume of 784,682. Merit Medical Systems, Inc. has a 52 week low of $59.74 and a 52 week high of $100.19. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.46 and a current ratio of 5.08. The firm has a market cap of $3.65 billion, a price-to-earnings ratio of 26.51, a P/E/G ratio of 1.91 and a beta of 0.58. The stock’s 50-day simple moving average is $69.44 and its 200 day simple moving average is $79.36.

Merit Medical Systems (NASDAQ:MMSI) last posted its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.10. Merit Medical Systems had a return on equity of 13.54% and a net margin of 9.03%.The business had revenue of $381.88 million during the quarter, compared to analysts’ expectations of $377.59 million. During the same quarter last year, the company posted $0.86 earnings per share. Merit Medical Systems’s quarterly revenue was up 7.4% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. On average, analysts expect that Merit Medical Systems, Inc. will post 3.61 earnings per share for the current fiscal year.

Institutional Trading of Merit Medical Systems

A number of institutional investors have recently bought and sold shares of MMSI. Lido Advisors LLC raised its position in shares of Merit Medical Systems by 3.8% in the 4th quarter. Lido Advisors LLC now owns 3,836 shares of the medical instruments supplier’s stock worth $324,000 after acquiring an additional 140 shares in the last quarter. AMI Asset Management Corp raised its position in shares of Merit Medical Systems by 0.8% in the 1st quarter. AMI Asset Management Corp now owns 21,818 shares of the medical instruments supplier’s stock worth $1,504,000 after acquiring an additional 168 shares in the last quarter. Maryland State Retirement & Pension System raised its position in shares of Merit Medical Systems by 2.1% in the 4th quarter. Maryland State Retirement & Pension System now owns 8,693 shares of the medical instruments supplier’s stock worth $766,000 after acquiring an additional 180 shares in the last quarter. Blue Trust Inc. raised its position in shares of Merit Medical Systems by 11.0% in the 4th quarter. Blue Trust Inc. now owns 1,853 shares of the medical instruments supplier’s stock worth $163,000 after acquiring an additional 184 shares in the last quarter. Finally, First Horizon Corp raised its position in shares of Merit Medical Systems by 19.7% in the 4th quarter. First Horizon Corp now owns 1,117 shares of the medical instruments supplier’s stock worth $98,000 after acquiring an additional 184 shares in the last quarter. Institutional investors own 99.66% of the company’s stock.

Wall Street Analysts Forecast Growth

MMSI has been the subject of a number of research analyst reports. Canaccord Genuity Group reduced their price objective on Merit Medical Systems from $90.00 to $85.00 and set a “buy” rating for the company in a report on Friday, May 1st. BTIG Research initiated coverage on shares of Merit Medical Systems in a research report on Friday, February 6th. They issued a “buy” rating and a $107.00 price target for the company. Citigroup reiterated an “outperform” rating on shares of Merit Medical Systems in a research report on Monday, April 20th. Needham & Company LLC dropped their price target on shares of Merit Medical Systems from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Finally, Weiss Ratings downgraded shares of Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Merit Medical Systems has a consensus rating of “Moderate Buy” and an average target price of $92.80.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.